Our Geno1® technology enables unprecedented advantages in the domain of liquid biopsies and beyond, by reducing costs and thus making next-generation diagnostic solutions accessible for any and all patients.
Liquid biopsies are part of a growing megatrend in cancer diagnostics, permitting non-invasive precision diagnostics and early detection of cancer. These novel diagnostic and therapeutic solutions are increasingly important in our aging societies. However, they are still non-accessible for the big majority of patients and there is room for improvement.
Our Geno1® technology derives from world class academic research conducted at MIT in US and ETH Zurich in Switzerland, latter generously supported by Bill & Melinda Gates Foundation.
The technology truly enables unprecedented scaling of liquid biopsies and beyond, by tackling the three main drivers: cost, accuracy and turn-around-time.
Expert in molecular biology, next-generation DNA sequencing and bioinformatics • Post-doctoral experience at MIT and ETH Zurich • Startup experience at a Harvard Medical School spin-off specializing in single cell transcriptomics
Experienced medtech & life science professional – with several years global experience in commercial functions LATAM, Switzerland, Nordics. • M.Sc Economics Sciences, M.Sc International Politics
MD, PhD in cardiology • International experience in clinical research functions & quality • Big pharma and clinical background
Experienced pediatric pathologist • Pediatric diseases and cancer • 84 scientific publications • Associate Professor
Master of Laws (LL.M) • Several years experience in life science and biotech • Specialities: M&As, startups, IPR
Professor of Human Genomics at University of Tartu • Head of Estonian Biobank Innovation Center • Research Scientist at Broad Institute of MIT and Harvard • Co-author in 350+ scientific publications • Among the 250 most influential scientist in the fields of molecular biology and genetics